Adam Cutler

Navidea Biopharmaceuticals Limited is a biotechnology company based out of 30 Upper High Street, Thame, Oxfordshire, United Kingdom.

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases, with an initial focus on personalized Rheumatoid Arthritis diagnostics. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com. Nasdaq: INM

Navidea Biopharmaceuticals Limited is a biotechnology company based out of 30 Upper High Street, Thame, Oxfordshire, United Kingdom.

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases, with an initial focus on personalized Rheumatoid Arthritis diagnostics. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com. Nasdaq: INM

The Trout Group is the leading investor relations and strategic advisory firm serving the life sciences and clean technology industries. Since 1996, we have been providing companies with expert advice and access to the institutional investment community. With more than a decade of experience in the biotechnology, pharmaceuticals, medical technology, life science technology and clean technology sectors, we offer our clients the relationships and knowledge base needed to clarify investment themes and reach the proper audience. Our global reach extends through a network of offices and contacts in all major financial centers, helping our clients find the right investors. Trout is headquartered in New York, with satellite offices in Boston, San Francisco, London, and Shanghai. Why are we called the Trout Group? The name of our firm highlights our commitment to working together as a firm and with our clients. In classical music, the quintet is the quintessential illustration of teamwork. Each member is an integral part of the team and by working in unison, a small, talented, smart group can sound like a grand symphony. A favorite of firm founder Jonathan Fassberg is a piano quintet by Franz Schubert, popularly called the Trout Quintet – hence The Trout Group. Trout Capital LLC, a securities broker-dealer and member of FINRA and the SIPC, is an affiliate of The Trout Group LLC and the two companies share common ownership.